Clinical Trials Directory

Trials / Completed

CompletedNCT06313164

The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes Patients

The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
217 (actual)
Sponsor
S.LAB (SOLOWAYS) · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This trial aims to assess the effectiveness of L-glutathione, supplemented with bioavailability boosters (tannin, low molecular weight chitosan, and polyethylene glycol), on improving antioxidant levels and glycemic control in patients with type 2 diabetes (T2D). The study is designed as a randomized, double-blind, placebo-controlled trial intending to enroll 240 T2D patients. The primary objective is to measure changes from baseline to 180 days in several key biomarkers, including endogenous reduced glutathione (GSH), oxidized glutathione (GSSG), 8-hydroxydeoxyguanosine (8-OHdG), and glycated hemoglobin (HbA1c), along with other metabolic parameters. Hypothesis: The anticipated outcome is a significant increase in GSH levels and a decrease in markers of oxidative damage among participants receiving L-glutathione compared to those in the placebo group, potentially indicating improved antioxidant defenses and some effects on glycemic regulation in T2D patients. This trial aims to fill gaps in current research regarding the role of L-glutathione supplementation in managing oxidative stress and metabolic control in diabetes.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTenhanced glutathioneL-glutathione (in combination with tannin, low molecular weight chitosan and polyethylene glycol)
OTHERplacebo comparatorplacebo group

Timeline

Start date
2023-06-20
Primary completion
2024-01-30
Completion
2024-02-29
First posted
2024-03-15
Last updated
2025-03-27

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT06313164. Inclusion in this directory is not an endorsement.